Literature DB >> 8174105

Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis.

F Ponchel1, A Puisieux, E Tabone, J P Michot, G Fröschl, A P Morel, T Frébourg, B Fontanière, F Oberhammer, M Ozturk.   

Abstract

Mutations affecting the p53 gene abrogate its tumor suppressor activity. It is, however, unclear whether such mutations can generate mutant p53 proteins with an intrinsic transforming ability. More importantly, the mechanism(s) by which they exert such activity is unknown. We report here that p53-deficient hepatoma cells (Hep3B) transfected with mutant p53-249ser (codon 249 Arg-->Ser) acquire a new phenotype with an increased in vitro survival and mitotic activity. However, such a phenotypic change is not sufficient to cause a major shift in the poor tumorigenic potential of these cells. This is apparently due to transforming growth factor beta 1-mediated apoptotic death of Hep3B cells which is not affected by the expression of p53-249ser.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174105

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

2.  neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice.

Authors:  B Li; J M Rosen; J McMenamin-Balano; W J Muller; A S Perkins
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

3.  p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53.

Authors:  A Ori; A Zauberman; G Doitsh; N Paran; M Oren; Y Shaul
Journal:  EMBO J       Date:  1998-01-15       Impact factor: 11.598

4.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

Authors:  M Müller; S Strand; H Hug; E M Heinemann; H Walczak; W J Hofmann; W Stremmel; P H Krammer; P R Galle
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

5.  Altered serum transforming growth factor-beta1 and monocyte chemoattractant protein-1 levels in obstructive jaundice.

Authors:  Shyr-Ming Sheen-Chen; Hock-Liew Eng; Kuo-Sheng Hung
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

6.  Cooperation of tumor-derived HBx mutants and p53-249(ser) mutant in regulating cell proliferation, anchorage-independent growth and aneuploidy in a telomerase-immortalized normal human hepatocyte-derived cell line.

Authors:  Weidong Jiang; Xin Wei Wang; Tamar Unger; Marshonna Forgues; Jin Woo Kim; S Perwez Hussain; Elise Bowman; Elisa A Spillare; Michael M Lipsky; Jeanne M Meck; Luciane R Cavalli; Bassem R Haddad; Curtis C Harris
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

7.  Characterization of the human Nalpha-terminal acetyltransferase B enzymatic complex.

Authors:  Amagoia Ametzazurra; Cristina Gázquez; Marta Lasa; Esther Larrea; Jesús Prieto; Rafael Aldabe
Journal:  BMC Proc       Date:  2009-08-04

8.  Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.

Authors:  Maike Sieben; Kerstin Herzer; Maja Zeidler; Vera Heinrichs; Barbara Leuchs; Martin Schuler; Jan-J Cornelis; Peter-R Galle; Jean Rommelaere; Markus Moehler
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

9.  Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells.

Authors:  Tian-Yi Chi; George G Chen; Lok-Kee Ho; Paul B S Lai
Journal:  Cancer Cell Int       Date:  2005-08-23       Impact factor: 5.722

10.  249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients.

Authors:  Jeronimo A Nogueira; Suzane K Ono-Nita; Marcelo E Nita; Marcelo M T de Souza; Eliane P do Carmo; Evandro S Mello; Cristovan Scapulatempo; Denise C Paranaguá-Vezozzo; Flair J Carrilho; Venancio A F Alves
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.